Search Within

Department of Medicine

Formats
  1. Journal Article (19620)
  2. Meeting Abstract (16084)
  3. Review (1158)
  4. Book Section (934)
  5. Editorial (611)
  6. Research Letter (316)
  7. Conference Paper (301)
  8. Guidelines (298)
  9. Correspondence (237)
  10. Miscellaneous (91)
  11. Book Whole (61)
Groups
  1. Solid Tumor Oncology Division (22367)
  2. Hematologic Malignancies, Division of (13308)
  3. Center for Hematologic Malignancies (11082)
  4. GSK Faculty (10658)
  5. Survivorship Research (9352)
  6. Division of Subspecialty Medicine (7560)

More Groups

People
  1. Robert Motzer (1251)
  2. Howard Scher (1133)
  3. Sergio Giralt (1069)
  4. Miguel-Angel Perales (943)
  5. Clifford Hudis (906)
  6. Jedd Wolchok (905)

More People

Years
  1. 2025 (1158)
  2. 2024 (2293)
  3. 2023 (2452)
  4. 2022 (2621)
  5. 2021 (2534)
  6. 2020 (2563)

More Years

Publications
  1. Journal of Clinical Oncology (6125)
  2. Blood (3722)
  3. Annals of Oncology (1411)
  4. Cancer Research (1238)
  5. Clinical Cancer Research (904)
  6. Biology of Blood and Marrow Transplantation (679)

More Publications

Publishers
  1. American Society of Clinical Oncology (6458)
  2. Elsevier Inc. (4216)
  3. American Society of Hematology (4003)
  4. American Association for Cancer Research (2898)
  5. Oxford University Press (2304)
  6. Nature Publishing Group (2122)

More Publishers

Results (39711)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Autologous cytotoxic T-cell receptor T cell therapy (SCG101) against hepatitis B surface antigen phase I/II trial for patients with advanced hepatitis B-related hepatocellular carcinoma
    Meeting Abstract

    Abou-Alfa, G. K.; Yong, W. P.; Chang, S. L.; Fan, J.; Toh, H. C.; Yau, T.; Choo, S.; Wang, J.; Kusuma, N.; Ma, C.; more...
    Journal of Clinical Oncology (2023)

    Fulltext@MSK | Save
  • MOUNTAINEER-03: Phase 3 study of tucatinib, trastuzumab, and modified FOLFOX6 as first line treatment in HER2+ metastatic colorectal cancer
    Meeting Abstract

    Bekaii-Saab, T. S.; Van Cutsem, E.; Tabernero, J.; Siena, S.; Yoshino, T.; Nakamura, Y.; Raghav, K. P. S.; Cercek, A.; Heinemann, V.; Adelberg, D. E.; more...
    Journal of Clinical Oncology (2023)

    Fulltext@MSK | Save
  • Phase II, single-arm, open-label study of dostarlimab monotherapy in previously untreated patients with stage II/III dMMR/MSI-H locally advanced rectal cancer
    Meeting Abstract

    Cercek, A.; Bachet, J. B.; Capdevila, J.; Starling, N.; Chen, E. X.; Di Bartolomeo, M.; Yoshino, T.; Vlahovic, G.; Zografos, E.; O'Donnell, S.; more...
    Journal of Clinical Oncology (2023)

    Fulltext@MSK | Save
  • Alliance A022104/NRG-GI010: A randomized phase II trial testing the efficacy of triplet versus doublet chemotherapy to achieve clinical complete response in patients with locally advanced rectal cancer—The Janus Rectal Cancer trial
    Meeting Abstract

    Smith, J. J.; Dasari, A.; Shi, Q.; Garcia-Aguilar, J.; Sanoff, H. K.; George, T. J.; Hong, T. S.; Yothers, G.; Philip, P. A.; Nelson, G. D.; more...
    Journal of Clinical Oncology (2023)

    Fulltext@MSK | Save
  • A randomized trial of consolidation-targeted adjuvant therapy with encorafenib and cetuximab versus usual care for patients with stage II/III BRAF V600E colon cancer: Alliance for Clinical Trials in Oncology A022004
    Meeting Abstract

    Yaeger, R.; Shi, Q.; Dueck, A. C.; Dib, E. G.; Kazmi, S. M. A.; Alese, O. B.; Krishnamurthi, S. S.; Nixon, A. B.; Shergill, A.; O'Reilly, E. M.; more...
    Journal of Clinical Oncology (2023)

    Fulltext@MSK | Save
  • Alliance A022102: Randomized phase III trial of mFOLFIRINOX +/- nivolumab vs. FOLFOX +/- nivolumab for first-line treatment of metastatic HER2-negative gastroesophageal adenocarcinoma (GEA)
    Meeting Abstract

    Park, H.; Geyer, S. M.; Klute, K.; Bleeker, J.; King, D.; Strickland, M.; Goodrich, A.; Carlisle, D.; Shergill, A.; O'Reilly, E. M.; more...
    Journal of Clinical Oncology (2023)

    Fulltext@MSK | Save
  • A multi-cohort phase I/IIa clinical trial to evaluate the safety, tolerability, and pharmacokinetics of TST001 administered as a monotherapy, with nivolumab or standard of care in patients with locally advanced or metastatic solid tumors: TransStar101
    Meeting Abstract

    Janjigian, Y. Y.; Sun, W.; Rocha Lima, C. M. S. P.; Shah, S.; Scott, A. J.; Monga, D. K.; Kundranda, M. N.; Sher, A. F.; Gold, P. J.; Berlin, J.; more...
    Journal of Clinical Oncology (2023)

    Fulltext@MSK | Save
  • A phase 1, open-label, dose escalation and dose expansion study to evaluate the safety, tolerability, pharmacokinetics, and antitumor activity of PF-07799933 (ARRY-440) as a single agent and in combination therapy in participants 16 years and older with advanced solid tumors with BRAF alterations
    Meeting Abstract

    Beck, J. T. T.; McKean, M.; Gadgeel, S. M.; Bowles, D. W.; Haq, R.; Yaeger, R.; Taylor, M. H.; Maity, A. K.; Drescher, S.; Oliver, C.; more...
    Journal of Clinical Oncology (2023)

    Fulltext@MSK | Save
  • Phase 2, multicenter, open-label basket trial of nab -sirolimus for patients with malignant solid tumors harboring pathogenic inactivating alterations in TSC1 or TSC2 genes (PRECISION I)
    Meeting Abstract

    Iyer, G.; Deming, D. A.; Demeure, M. J.; Federman, N.; McKean, M.; Lee, E. K.; Spira, A. I.; Kwiatkowski, D. J.; Hussein, M. A.; Gordon, E. M.; more...
    Journal of Clinical Oncology (2023)

    Fulltext@MSK | Save
  • BREAKWATER: An open-label, multicenter, randomized, phase 3 study, with a safety lead-in (SLI), of first-line (1L) encorafenib (E) + cetuximab (C) ± chemotherapy (CT) vs standard-of-care (SOC) CT for BRAF V600E-mutant metastatic colorectal cancer (mCRC)
    Meeting Abstract

    Kopetz, S.; Yoshino, T.; Kim, T. W.; Wasan, H. S.; Van Cutsem, E.; Ciardiello, F.; Maughan, T. S.; Eng, C.; Yaeger, R.; Desai, J.; more...
    Journal of Clinical Oncology (2023)

    Fulltext@MSK | Save